There is a new world opening up in ocular therapeutics.

Eyenovia is making it possible with development programs in progressive myopia, glaucoma, mydriasis, and dry eye.

Microdose formulation technology designed to be easier, smarter, safer and better tolerated

.

It's a big deal

A PORTFOLIO OF CLINICAL ASSETS AND INTELLECTUAL PROPERTY

The Eyenovia clinical pipeline targets high-value eye diseases

Our intellectual property portfolio includes 8 issued/allowed and 7 pending patents in U.S. and 27 issued/allowed and 54 pending patents worldwide

Approximate Number in US Affected by Eyenovia’s Targeted Conditions*

0 *1
Myopia
0 *2
Glaucoma and Ocular Hypertension
0 *3
Annual dilations for eye exams
0 *4
Dry Eye Symptoms

Easier For Patients

Horizontal drug installation with less waste and spillage

Smarter Technology

Dosing reminders and tracking

Safer

Potential to reduce systemic drug exposure.

Better Tolerated

Reduced exposure to active ingredients and preservatives while maintaining efficacy

On the forefront of technology

High precision micro-dosing minimizes toxicity leading to more efficient and gentler treatment.

Play Video
Play Video

- EYENOVIA PRICES PUBLIC OFFERING OF COMMON STOCK

- EYENOVIA COMPLETES PATIENT ENROLLMENT IN MICROSTAT MIST-1 STUDY AND ENROLLS FIRST PATIENT IN MIST-2 STUDY

- EYENOVIA ANNOUNCES PUBLICATION OF ITS PG21 PHASE II TRIAL RESULTS DEMONSTRATING ROBUST IOP LOWERING EFFECT AND PATIENT USABILITY

TRADED GLOBALLY

For quarterly updates on our progress with our phase 3 programs, or for any other questions, please provide us with your name and email address below.

Our microdosing technology is poised to transform the standard of care in ophthalmic therapeutic delivery.

295 Madison Aveue
Suite 2400
New York, NY 10017

+1 (917) 289-1117

*1 UpToDate (2018); HCW Analyst Report (2018); Chia et. al, Am J Ophthalmol. (2014); Vitale et. al, Arch Ophthalmol, (2009); Theophanous et. al, (2018), US Census Bureau

*2  UpToDate (2018), GlobalData (2017), 2012 Fifth Edition of Vision Problems in the U.S., Friedman et. Al, Am J Ophthalmol (2004);Prostaglandin Analogues in Angle-Closure Glaucoma, Gupta et. Al, 2011; American Academy of Ophthalmology; Transparency Market Research; The Ophthalmologist; ProPublica

*3  1National Health Interview Survey, CDC (2017); Fernando A. et al., Journal of Ophthalmology (2015); Lindstrom et al., 2015; Infection control in the eyecare office (2013)

*4 2012 Gallup Poll

Close Menu